CLINDAMYCIN PHOSPHATE AND TRETINOIN Drug Patent Profile
✉ Email this page to a colleague
When do Clindamycin Phosphate And Tretinoin patents expire, and when can generic versions of Clindamycin Phosphate And Tretinoin launch?
Clindamycin Phosphate And Tretinoin is a drug marketed by Actavis Mid Atlantic, Encube, and Solaris Pharma Corp. and is included in three NDAs.
The generic ingredient in CLINDAMYCIN PHOSPHATE AND TRETINOIN is clindamycin phosphate; tretinoin. There are fifty-five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the clindamycin phosphate; tretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindamycin Phosphate And Tretinoin
A generic version of CLINDAMYCIN PHOSPHATE AND TRETINOIN was approved as clindamycin phosphate; tretinoin by ACTAVIS MID ATLANTIC on June 12th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLINDAMYCIN PHOSPHATE AND TRETINOIN?
- What are the global sales for CLINDAMYCIN PHOSPHATE AND TRETINOIN?
- What is Average Wholesale Price for CLINDAMYCIN PHOSPHATE AND TRETINOIN?
Summary for CLINDAMYCIN PHOSPHATE AND TRETINOIN
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 9 |
| DailyMed Link: | CLINDAMYCIN PHOSPHATE AND TRETINOIN at DailyMed |
Recent Clinical Trials for CLINDAMYCIN PHOSPHATE AND TRETINOIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alphacait, LLC | Phase 2 |
| Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| Zeichner, Joshua, M.D. | Phase 4 |
Pharmacology for CLINDAMYCIN PHOSPHATE AND TRETINOIN
| Drug Class | Lincosamide Antibacterial Retinoid |
| Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
US Patents and Regulatory Information for CLINDAMYCIN PHOSPHATE AND TRETINOIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | CLINDAMYCIN PHOSPHATE AND TRETINOIN | clindamycin phosphate; tretinoin | GEL;TOPICAL | 202564-001 | Jun 12, 2015 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Encube | CLINDAMYCIN PHOSPHATE AND TRETINOIN | clindamycin phosphate; tretinoin | GEL;TOPICAL | 216943-001 | Sep 1, 2023 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Solaris Pharma Corp | CLINDAMYCIN PHOSPHATE AND TRETINOIN | clindamycin phosphate; tretinoin | GEL;TOPICAL | 212845-001 | Feb 10, 2022 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
